{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Allogeneic+Transplant&page=9",
    "query": {
      "intervention": "Allogeneic Transplant",
      "page": 9
    },
    "page_size": 10
  },
  "pagination": {
    "page": 9,
    "page_size": 10,
    "total_count": 1596,
    "total_pages": 160,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Allogeneic+Transplant&page=10&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Allogeneic+Transplant&page=8&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-15T10:47:49.007Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00533923",
      "title": "Nonmyeloablative Allogeneic Stem Cell Transplantation From HLA-Matched Unrelated Donor for the Treatment of Hematologic Disorders",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "AML",
        "ALL",
        "CLL",
        "Myelodysplastic Syndrome",
        "Non-Hodgkin's Lymphoma",
        "Hodgkin's Lymphoma",
        "Multiple Myeloma",
        "Aplastic Anemia",
        "Myeloproliferative Disorder"
      ],
      "interventions": [
        {
          "name": "Cyclophosphamide; Fludarabine; Cyclosporin; CAMPATH-1H (Alemtuzumab); GM-CSF",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Beth Israel Deaconess Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "Up to 65 Years"
      },
      "enrollment_count": 25,
      "start_date": "2002-12",
      "completion_date": "2007-01",
      "has_results": false,
      "last_update_posted_date": "2016-07-18",
      "last_synced_at": "2026-11-15T10:47:49.007Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00533923"
    },
    {
      "nct_id": "NCT00185640",
      "title": "Allogeneic Transplantation Using Total Lymphoid Irradiation (TLI) and Anti-Thymocyte Globulin (ATG) for Older Patients With Hematologic Malignancies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Blood Cancer",
        "Leukemia"
      ],
      "interventions": [
        {
          "name": "Cyclosporine",
          "type": "DRUG"
        },
        {
          "name": "Anti-thymocyte globulin (ATG)",
          "type": "DRUG"
        },
        {
          "name": "Mycophenolate mofetil (MMF)",
          "type": "DRUG"
        },
        {
          "name": "Filgrastim",
          "type": "DRUG"
        },
        {
          "name": "Total Lymphoid Irradiation (TLI)",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "Stanford University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "50 Years to 70 Years"
      },
      "enrollment_count": 303,
      "start_date": "2003-03",
      "completion_date": "2016-01",
      "has_results": true,
      "last_update_posted_date": "2021-06-29",
      "last_synced_at": "2026-11-15T10:47:49.007Z",
      "location_count": 1,
      "location_summary": "Stanford, California",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00185640"
    },
    {
      "nct_id": "NCT07646210",
      "title": "HiCM-188 Cell Therapy in Adults With Advanced Heart Failure Undergoing Heart Bypass Surgery",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced Heart Failure",
        "Ischemic Heart Failure"
      ],
      "interventions": [
        {
          "name": "HiCM-188 Cells",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "HELP Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 12,
      "start_date": "2027-02",
      "completion_date": "2029-02",
      "has_results": false,
      "last_update_posted_date": "2026-11-10",
      "last_synced_at": "2026-11-15T10:47:49.007Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07646210"
    },
    {
      "nct_id": "NCT02485535",
      "title": "Selinexor in Treating Patients With Intermediate- and High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome After Transplant",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Acute Myeloid Leukemia",
        "de Novo Myelodysplastic Syndrome",
        "Myelodysplastic Syndrome",
        "Secondary Acute Myeloid Leukemia",
        "Secondary Myelodysplastic Syndrome"
      ],
      "interventions": [
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Selinexor",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "University of Chicago",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 12,
      "start_date": "2015-09-04",
      "completion_date": "2020-07",
      "has_results": false,
      "last_update_posted_date": "2021-05-13",
      "last_synced_at": "2026-11-15T10:47:49.007Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02485535"
    },
    {
      "nct_id": "NCT00186823",
      "title": "Haploidentical Stem Cell Transplantation for Patients With Hematologic Malignancies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Leukemia, Acute Lymphocytic (ALL)",
        "Leukemia, Myeloid, Acute(AML)",
        "Leukemia, Myeloid, Chronic(CML)",
        "Juvenile Myelomonocytic Leukemia(JMML)",
        "Hemoglobinuria, Paroxysmal Nocturnal (PNH)",
        "Lymphoma, Non-Hodgkin (NHL)",
        "Myelodysplastic Syndrome (MDS)"
      ],
      "interventions": [
        {
          "name": "Miltenyi Biotec CliniMACS",
          "type": "DEVICE"
        },
        {
          "name": "Stem Cell Transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "TBI, systemic chemotherapy and antibodies as follows:",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "St. Jude Children's Research Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "2 Years to 21 Years"
      },
      "enrollment_count": 57,
      "start_date": "2002-03",
      "completion_date": "2009-01",
      "has_results": false,
      "last_update_posted_date": "2009-01-29",
      "last_synced_at": "2026-11-15T10:47:49.007Z",
      "location_count": 1,
      "location_summary": "Memphis, Tennessee",
      "locations": [
        {
          "city": "Memphis",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00186823"
    },
    {
      "nct_id": "NCT02737306",
      "title": "A Study of Acute Graft-Versus-Host Disease (GVHD) in Patients Undergoing Allogeneic Stem-Cell Transplantation",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Graft Vs Host Disease"
      ],
      "interventions": [
        {
          "name": "PRO 140",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "CytoDyn, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 11,
      "start_date": "2017-05-14",
      "completion_date": "2021-09-30",
      "has_results": true,
      "last_update_posted_date": "2024-03-12",
      "last_synced_at": "2026-11-15T10:47:49.007Z",
      "location_count": 8,
      "location_summary": "Miami, Florida • Maywood, Illinois • Detroit, Michigan + 5 more",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Maywood",
          "state": "Illinois"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "Winston-Salem",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02737306"
    },
    {
      "nct_id": "NCT02846376",
      "title": "Single Agent and Combined Inhibition After Allogeneic Stem Cell Transplant",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Acute Myeloid Leukemia and Myelodysplastic Syndrome"
      ],
      "interventions": [
        {
          "name": "Nivolumab",
          "type": "DRUG"
        },
        {
          "name": "Ipilimumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hackensack Meridian Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 8,
      "start_date": "2019-03-08",
      "completion_date": "2023-12-21",
      "has_results": false,
      "last_update_posted_date": "2024-11-18",
      "last_synced_at": "2026-11-15T10:47:49.007Z",
      "location_count": 1,
      "location_summary": "Hackensack, New Jersey",
      "locations": [
        {
          "city": "Hackensack",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02846376"
    },
    {
      "nct_id": "NCT00887068",
      "title": "Controlled Study of Post-transplant Azacitidine for Prevention of Acute Myelogenous Leukemia and Myelodysplastic Syndrome Relapse (VZ-AML-PI-0129)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Leukemia",
        "AML",
        "MDS"
      ],
      "interventions": [
        {
          "name": "Azacitidine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 187,
      "start_date": "2009-04-21",
      "completion_date": "2018-08-20",
      "has_results": true,
      "last_update_posted_date": "2020-01-14",
      "last_synced_at": "2026-11-15T10:47:49.007Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00887068"
    },
    {
      "nct_id": "NCT00282438",
      "title": "Hematopoietic Stem Cell Support in Patients With Refractory Sarcoidosis",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Sarcoidosis"
      ],
      "interventions": [
        {
          "name": "Autologous hematopoietic stem cell transplantation",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Allogeneic stem cell transplantation",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Northwestern University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 2,
      "start_date": "2003-12",
      "completion_date": "2015-08",
      "has_results": true,
      "last_update_posted_date": "2018-08-31",
      "last_synced_at": "2026-11-15T10:47:49.007Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00282438"
    },
    {
      "nct_id": "NCT00702403",
      "title": "Nilotinib and Imatinib Mesylate After Donor Stem Cell Transplant in Treating Patients With ALL or CML",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Accelerated Phase Chronic Myelogenous Leukemia",
        "Adult Acute Lymphoblastic Leukemia in Remission",
        "Blastic Phase Chronic Myelogenous Leukemia",
        "Childhood Acute Lymphoblastic Leukemia in Remission",
        "Childhood Chronic Myelogenous Leukemia",
        "Chronic Myelogenous Leukemia, BCR-ABL1 Positive",
        "Chronic Phase Chronic Myelogenous Leukemia",
        "Philadelphia Positive Adult Acute Lymphoblastic Leukemia",
        "Philadelphia Positive Childhood Acute Lymphoblastic Leukemia",
        "Recurrent Adult Acute Lymphoblastic Leukemia",
        "Recurrent Childhood Acute Lymphoblastic Leukemia",
        "Relapsing Chronic Myelogenous Leukemia",
        "Untreated Adult Acute Lymphoblastic Leukemia",
        "Untreated Childhood Acute Lymphoblastic Leukemia"
      ],
      "interventions": [
        {
          "name": "nilotinib",
          "type": "DRUG"
        },
        {
          "name": "imatinib mesylate",
          "type": "DRUG"
        },
        {
          "name": "pharmacological study",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Fred Hutchinson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 40,
      "start_date": "2008-08-14",
      "completion_date": "2013-12-01",
      "has_results": true,
      "last_update_posted_date": "2017-08-10",
      "last_synced_at": "2026-11-15T10:47:49.007Z",
      "location_count": 5,
      "location_summary": "Stanford, California • Tampa, Florida • Portland, Oregon + 1 more",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00702403"
    }
  ]
}